ClinicalTrials.gg
Not yet recruitingNCT06017635Updated Aug 30, 2023

Non-invasive Monitoring and Serum Marker Study in Children With Cerebral Edema

An observational study in Brain Edema, sponsored by Qilu Hospital of Shandong University. Not yet recruiting. Open to participants aged 12 Months to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Qilu Hospital of Shandong University · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
264
Ages
12 Months to 18 Years
Sex
All
01

Study summary

Purpose of the study:This study aimed to evaluate the clinical significance of serum SUR1, TRPM4 and MMP-9 in the diagnosis of cerebral edema in children with cerebral edema admitted to PICU by comparing them with CT results and perturbation coefficients, so as to provide biological indicators for clinical diagnosis of cerebral edema and provide targets for the treatment of cerebral edema in various diseases.

Read the detailed description

Early and efficient use of various measures to control and monitor peripheral cerebral edema and intracranial pressure, timely and accurate adjustment of treatment plan to reduce the degree of cerebral edema and reduce intracranial pressure, can significantly improve the development of the disease and prognosis recovery. At present, the clinical diagnosis of cerebral edema is mainly through clinical manifestations and imaging examinations, and there is a lack of corresponding biological examination methods.Purpose of the study:1.By analyzing the correlation between serum SUR1, TRPM4, MMP-9 and the electromagnetic disturbance coefficient, cranial CT results, Glasgow coma score, S100-β, NSE and prognostic score at 3 months of discharge, the clinical value of serum SUR1, TRPM4, MMP-9 and perturbation coefficient in the diagnosis, intracranial pressure monitoring, condition assessment and prognosis judgment of cerebral edema in children was explored.2.By analyzing the changes of the above indicators in various children with cerebral edema admitted to PICU, the types of cerebral edema and the cellular and molecular mechanisms of cerebral edema caused by different diseases were explored.

02

Conditions studied

  • Brain Edema

Browse trials for

03

In context

Brain Edema

102 studies on the registry are indexed under Brain Edema; 25 are open to participants now.

This study's planned enrollment of 264 is above the median of 88 across 31 observational studies indexed under Brain Edema.

Browse Brain Edema studies →

Lead sponsor

Qilu Hospital of Shandong University is the lead sponsor of 310 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children whose PICU income meets the inclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1-18 years old, male or female
  • Diagnosed with cerebral contusion/cerebral hemorrhage/intracranial tumor postoperative / intracranial infection/septic encephalopathy/metabolic encephalopathy.
  • The research purpose, significance, risks, benefits, and of patients and their families to the study.

Exclusion criteria

Exclusion Criteria:

  • Critically ill and not suitable for research.
  • Those who are allergic to electrode sheets and do not cooperate.
  • Age> 18 years old or \< 1 month.
  • Failure to obtain written permission from the guardian.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
264 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case

    1. Age 1-18 years old, male or female. 2. Diagnosed with cerebral contusion/cerebral hemorrhage/intracranial tumor postoperative / intracranial infection/septic encephalopathy/metabolic encephalopathy. 3. The research purpose, significance, risks, benefits, and informed consent of patients and their families to the study.

    Other: Exposure factors

  • Contral

    1. Age 1-18 years old, male or female. 2. Non-cranial organic injury diseases. 3. Physical condition allows them to participate in the study. 4. The research purpose, significance, risks, benefits, and informed consent of patients and their families to the study.

    Other: Exposure factors

Interventions

  • OtherExposure factors

    1. General information Name, gender, age, weight (kg), major diseases 2. Clinical data: Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge.

06

What researchers measure

Primary outcomes

  1. Serum SUR1 concentration

    Time frame: On days 1, 4, 7, and 14 of enrollment

  2. Serum TRPM4 concentration

    Time frame: On days 1, 4, 7, and 14 of enrollment

  3. Serum MMP-9 concentration

    Time frame: On days 1, 4, 7, and 14 of enrollment

  4. Perturbation coefficient monitored by noninvasive cerebral edema monitor

    Time frame: On days 1, 4, 7, and 14 of enrollment

  5. Area of cerebral edema as shown on cranial CT

    Time frame: Day 1 of admission

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Mar 2024, 6 months later.

Of 15 observational studies under Brain Edema, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 30, 2023
StartEst.
Aug 31, 2023
Primary completionEst.
Mar 1, 2024
CompletionEst.
Aug 31, 2024
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06017635
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Aug 31, 2023 (estimated)
Primary completion
Mar 1, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Aug 30, 2023

Study contacts

Teng Wang
Contact
w2311954128@163.com
17861522291
XinJie Liu
Contact
liuxinjie-ert@163.com
18560086300
XinJie Liu
study director · Director of Qilu Hospital of Shandong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion